AngioDynamics (NASDAQ: ANGO) reported Q3 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $66 million versus the consensus estimate of $75.73 million.

GUIDANCE:

AngioDynamics sees FY2024 EPS of ($0.54)-($0.58), versus the consensus of ($0.43). AngioDynamics sees FY2024 revenue of $270-275 million, versus the consensus of $312.1 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.